GNS561, a clinical-stage PPT1 inhibitor, is efficient against hepatocellular carcinoma via modulation of lysosomal functions
S. BRUN, E. Raymond, F. Bassissi, Z. M. Jilkova, S. Mezouar, M. Rachid, M. Novello, J. Tracz, A. Hamai, G. Lalmanach, L. Vanderlynden, E. Bestion, R. Legouffe, J. Stauber, T. Schubert, , P. Halfon
This paper evaluates GNS561, a PPT1 inhibitor, showing its efficacy against HCC by modulating lysosomal functions and inducing cell death in vitro and in vivo.
bioRxiv · Sep 30, 2020Cancer Biology